LEADERSHIP TEAM

Ian J. Massey D.Phil.

Ian J. Massey D.Phil. – Chief Executive Officer

Dr. Massey has over 30 years of pharmaceutical industry experience in all phases of research and development, from target selection through to NDA approval. Dr. Massey has founded, built and successfully exited several biotech companies. His primary focus has been in small molecule and protein therapeutics in multiple therapeutic areas. Dr. Massey has a D.Phil. from the University of Oxford (England) and performed post-doctoral work with Carl Djerassi at Stanford. He was formerly Head of Research and Early Development at Roche Pharmaceuticals (Palo Alto), founder and CEO of Synosia Therapeutics, President of Biotie Therapeutics and CEO of StemCell Inc.

Richard G Farrell

Richard G Farrell – Chief Financial Officer

Richard is a former Investment Banker with over 23 years of experience in finance, M&A, capital raises and corporate restructures in Australia and the United States. Richard has been founder and CFO of several companies and was formerly an Investment Banker with Beerworth & Partners in Sydney Australia, where he advised on takeovers and private placements. Prior to that, Richard was with Ernst & Young Corporate Finance and formerly Deloitte Touché Corporate Finance. Richard has a BComm. (Australian National University), LLB (Australian National University) and a Graduate Diploma in Finance & Investment (Finsia).

Srinivas Rao, M.D., Ph.D.

Srinivas Rao, M.D., Ph.D. – Chief Medical Officer

Dr. Rao was formerly CEO of Kyalin Biosciences and has been the Chief Medical Officer of multiple biotech companies, including Axial Biotheraputics, Inc., Deposed, Inc. and Kayla Pharmaceuticals. He holds an MD in Internal Medicine from Yale University School of Medicine and a PhD in Neuropharmacology from Yale University. Dr. Rao has also been an advisory board member to UCSD SDTA and HUYA Bioscience international.

David G. Putman Ph.D.

David G. Putman Ph.D. – Chief Scientific Officer

Dr. Putman has more than 25 years of scientific and management experience in large and small pharmaceutical companies, including Syntex, Roche, UCB and Kadmus. Dr. Putman co-founded Anvyl LLC, a biotech that is developing cutting-edge therapies to address disorders of the central nervous system (CNS). Anvyl was founded with the goal of providing safe and efficacious therapies currently desperately needed for treating CNS conditions, like cognitive-deficit disorders, anxiety and pain. Using its expertise in allosteric modulation, Anvyl is creating a broad pipeline of first-in-class drugs to fill unmet medical conditions including Alzheimer’s disease, schizophrenia, autism spectrum disorder, traumatic brain injury and other CNS disorders such as epilepsy, anxiety and pain. Dr. Putman has a BS in Chemical Engineering, a Ph.D. in Organic Chemistry and was a postdoctoral fellow at Cornell University.

Olivier Dasse Ph.D.

Olivier Dasse Ph.D. – Vice President of Chemistry

Dr. Dasse has 18 years of drug discovery and development experience that resulted in multiple preclinical and clinical candidates. Dr. Dasse co-founded Anvyl LLC, a company focused on the development of nicotinic and gabaergic positive allosteric modulators for the treatment of central nervous system disorders. Dr. Dasse served as program leader at Kadmus pharmaceuticals where he spearheaded medicinal chemistry efforts on inhibitors of fatty acid amide hydrolase, the main enzyme involved in endo-cannabinoid pharmacology. The program was sold to Organon for $270M. Prior to Kadmus, Dr. Dasse served as a senior scientist at UCB pharma where he conducted research on anti-inflammatory chemokine antagonists. Dr. Dasse has co-authored over 30 published scientific publications and patents. Dr. Dasse also served as an instructor/researcher in the French Military Forensics Institute. There, he worked on the development of methods for gun powder residue dating by UV spectroscopy as well as blood print enhancement  by luminescence. Dr. Dasse earned his Ph.D. in organic chemistry at Florida State University where he worked on the total synthesis of anti-histaminic natural product steroids. He also earned his diplôme d’ingénieur from Ecole Supérieure de Chimie Organique et Minérale, Paris, France.

Georgina Kilfoil, BSc, PMP

Georgina Kilfoil, BSc, PMP – Clinical Project Management and Operations

Georgina has a proven track record in building, growing, and financing life-science ventures with specific expertise in strategic drug development, operational project management, and clinical plan execution.

  • Executive level Life Science professional with more than 30 years of cross-functional experience in areas critical to the success of emerging and established bio-pharmaceutical companies, including: project evaluation, planning and management, strategic portfolio planning, management and integration, vendor identification and management, clinical planning and oversight.
  • Demonstrated effectiveness in creating operational, strategic and leadership processes essential to attaining milestones and bringing innovation to fruition.
  • Part of senior leadership team for over $500M in private and public capital debt and equity financing and for over US$1.2B in acquisitions.
  • Led infectious disease, cardiovascular and oncology programs, translating commercial rationales into executable global business strategies. Includes over twenty global Phase 2 and Phase 3 studies with enrolment sizes up to 6500 patients and budgets up to $100m.
  • Expertise in building virtual and semi-virtual project teams to expeditiously and cost effectively move programs in a wide range of therapeutic areas through the development process from early pre-clinical to NDA filing.
  • Played key roles in the development and successful NDA filings for 4 anti-infectives (Eraxis®, Doribax®, Teflaro®, Zerbaxa®) and multiple pre-NDA projects.

Georgina is a certified Project Management Professional, has a Bachelor of Science degree (Honours) in Pharmacology from the University of Bristol, United Kingdom, and a Master of Business Administration degree from the Australian Graduate School of Management, Sydney, Australia.

Yvonne Sandner CPA MBA

Yvonne Sandner CPA, MBA – Financial Controller (Consultant)

Yvonne has been Chief Financial Officer and Financial Controller of several companies, including Westum (CFO), Camalize, S.L. (Controller), Durata Therapeutics, Inc., (Controller), Scytl Secure Electronic Voting, S.A Barcelona, Spain (VP and Corporate Controller) and BorgWarner – Lombardia, Italy (Controller) and  Delphi Energy & Engine Management Systems (Cost Analyst/Accountant). Yvonne setup and implemented NetSuite for GABA Therapeutics, and overseas the preparation of the company’s international consolidated financial statements.

Yvonne has a Master of Business Administration (MBA): DePaul University (Chicago, IL, USA), 2003, a Bachelor of Arts: Michigan State University (East Lansing, MI, USA), 1997 Accounting and is a Certified Public Accountant (CPA) (Illinois, USA).

Mary Richardson, PhD DABT

Mary Richardson, PhD DABT – Preclinical Safety, Pharmacology And Toxicology

Mary Richardson is currently executive Vice President and Chief Scientific Officer at iuvo Bioscience, a Rochester –based R+D contract research organization. She also leads the Lumino Advisors Consulting team at iuvo BioScience and serves as a consultant for both pharmaceutical and medical device programs which involves all aspects of serving as a preclinical representative including creating and executing testing programs, issue management and preparation and defense of regulatory submissions.

She is an experienced board-certified Toxicologist (Diplomate of American Board of Toxicology; DABT) with broad-based technical skills in preclinical drug development. Mary earned her Ph.D. in Toxicology from the University of Rochester.  Prior to her current role, she has held executive leadership positions at Procter and Gamble and Bausch and Lomb.

Her technical leadership in Preclinical drug development of small molecules, peptides, and medical devices has resulted in Regulatory approval and success of numerous drugs and medical devices. She has been an invited speaker at several scientific meetings and is an author on numerous publications.

Thomas R. Malefyt, Ph.D.

Thomas R. Malefyt, Ph.D. – CMC, API and Drug Product

  • 35+ years’ experience in management, oversight, and execution of Chemistry Manufacturing & Controls efforts in small and large pharmaceutical companies
  • Responsible for the CMC pharmaceutical development programs for both large and small molecules, and at both early and late stages of development
  • Serving early-development pharmaceutical companies to utilize established Contract Development and Manufacturing Organizations to provide comprehensive CMC services including: planning, risk assessment, due diligence, management oversight for the manufacture of materials, and the development, transfer and validation of analytical methodologies; guidance for drug product formulation efforts, process development, GMP manufacturing, packaging, stability evaluation, and the preparation of CMC regulatory documentation.

Formerly

  • Biotie Therapies (2006 – 2014): Vice President of CMC Operations,
  • Admunex Therapeutics (2001 – 2003): President and Chief Operating Officer,
  • Roche Bioscience (1995 – 1996): Director
  • Syntex Research: Institute of Pharmaceutical. Sciences (1988 – 1995): Research Section Leader, Department Head, CMC Leader, Director
  • Syntex Corporation (1991-1992): Special Assistant to the President and COO
  • SmithKline and French Laboratories (1984 – 1988): Senior. and Assoc. Research Investigator,
  • Pharmaceutical CMC Consulting Services (2003 – 2006 and 2014 to present):

Education

  • D. Physical Organic Chemistry, University of California at Santa Barbara
  • MS Biochemistry, California State Polytechnic University, Pomona, CA
  • BS Biology, California State Polytechnic University, Pomona, CA
Alan Peebles